Mirum Pharmaceuticals
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 264
- Market Cap
- $2.1B
- Website
- http://www.mirumpharma.com
- Introduction
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.
Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease
- Conditions
- First Posted Date
- 2014-05-06
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT02131623
- Locations
- π¨π¦
The Hospital for Sick Children, Toronto, Ontario, Canada
πΊπΈPhoenix Childrens Hospital, Phoenix, Arizona, United States
πΊπΈChildren's Hospital Colorado, Aurora, Colorado, United States
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2021-07-01
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT02117713
- Locations
- πΊπΈ
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
πΊπΈSeattle Children's Hospital, Seattle, Washington, United States
πΊπΈRiley Hospital for Children, Indianapolis, Indiana, United States
Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis
- First Posted Date
- 2014-02-13
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT02061540
- Locations
- πΊπΈ
Duke University, Durham, North Carolina, United States
π¨π¦University of Calgary Liver Unit, Calgary, Alberta, Canada
π¨π¦University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada
Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis
- Conditions
- Interventions
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT02057718
- Locations
- πΊπΈ
Children's Hospital Los Angeles, Los Angeles, California, United States
π΅π±The Children's Memorial Health Institute, Warsaw, Poland
π«π·Hopital Femme Mere Enfant De Lyon, Bron, France
Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT02057692
- Locations
- πΊπΈ
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
π¨π¦The Hospital for Sick Children, Toronto, Ontario, Canada
πΊπΈAnn & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT02047318
- Locations
- π¬π§
Leeds Teaching Hospital NHS Trust, Leeds, West Yorkshire, United Kingdom
π¬π§Birmingham Children's Hospital, Birmingham, West Midlands, United Kingdom
π¬π§Kings College Hospital, London, United Kingdom
Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2013-07-22
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT01904058
- Locations
- πΊπΈ
Minnesota Gastroenterology, Saint Paul, Minnesota, United States
πΊπΈHenry Ford Health System, Detroit, Michigan, United States
πΊπΈScripps Clinic, La Jolla, California, United States
Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2019-03-28
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01903460
- Locations
- π¬π§
Kings College Hospital, London, United Kingdom
π¬π§Birmingham Children's Hospital, Birmingham, West Midlands, United Kingdom
π¬π§Leeds Teaching Hospitals, Leeds, West Yorkshire, United Kingdom
Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis
- First Posted Date
- 2011-09-22
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT01438411
- Locations
- πΊπΈ
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis
- First Posted Date
- 2010-05-04
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Mirum Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT01115582
- Locations
- πΊπΈ
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States